Organon & Co.

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

OGN$13.85-0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Product and Geographic Information

Product and Geographic Information

Revenues of the Company’s products were as follows:

	Year Ended December 31,
2025 · 2024 · 2023
($ in millions)	U.S.	Int’l	Total	U.S.	Int’l	Total	U.S.	Int'l	Total
Women’s Health
Nexplanon/Implanon NXT	$610	$311	$921	$672	$291	$963	$572	$257	$830
Follistim AQ	112	152	264	84	152	237	125	136	262
NuvaRing	19	72	91	39	75	115	90	86	176
Ganirelix Acetate Injection	12	89	101	20	89	109	—	134	134
Marvelon/Mercilon	—	127	127	—	134	134	19	91	110
Jada	73	1	74	60	1	61	43	—	43
Other Women’s Health (1)	65	109	174	56	104	158	48	101	147
General Medicines
Biosimilars
Renflexis	183	69	251	219	55	274	234	43	278
Hadlima	166	62	228	104	38	142	17	26	44
Ontruzant	15	84	99	29	112	141	46	109	155
Brenzys	—	80	80	—	77	77	—	73	73
Other Biosimilars (1)	17	16	33	—	28	28	—	43	43
Established Brands
Cardiovascular
Atozet	—	324	324	—	473	473	—	519	519
Zetia	5	337	342	7	310	317	8	314	322
Cozaar/Hyzaar	8	211	219	9	234	243	10	272	281
Vytorin	4	96	100	6	102	108	6	124	129
Rosuzet	—	24	24	—	49	49	—	70	70
Other Cardiovascular (1)	3	124	126	2	130	133	2	136	139
Respiratory
Singulair	8	244	252	9	350	359	11	393	404
Nasonex	—	261	262	—	276	276	—	266	266
Dulera	113	39	153	162	42	203	156	38	194
Clarinex	2	121	123	3	125	127	5	132	136
Other Respiratory (1)	42	12	52	38	13	53	49	14	64
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—	265	265	—	270	270	—	257	257
Fosamax	2	141	143	3	147	151	3	156	159
Diprospan	—	150	150	—	139	139	—	91	91
Vtama	111	17	128	10	1	12	—	—	—
Other Non-Opioid Pain, Bone and Dermatology (1)	16	285	301	19	279	295	14	261	275
Other
Propecia	6	112	118	6	105	111	7	118	125
Emgality	—	174	174	—	107	107	—	—	—
Proscar	1	96	97	1	94	95	1	96	97
Other (1)	10	327	338	14	314	328	13	308	319
Other (2)	1	80	82	—	115	115	(1)	121	121
Revenues	$1,604	$4,612	$6,216	$1,572	$4,831	$6,403	$1,478	$4,785	$6,263

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately.

(2) Includes manufacturing sales to third parties.

-79-

Revenues by geographic area where derived are as follows:

	Year EndedDecember 31,
($ in millions)	2025	2024	2023
Europe and Canada	$1,618	$1,763	$1,673
United States	1,604	1,572	1,478
Asia Pacific and Japan	1,000	1,050	1,129
China	829	847	864
Latin America, Middle East, Russia, and Africa	1,072	1,034	965
Other (1)	93	137	154
Revenues	$6,216	$6,403	$6,263

(1) Includes manufacturing sales to third parties.

As of December 31, 2025, approximately 75% of the Company’s long-lived fixed assets are located in Europe and Canada, and 17% are in the United States. The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.